{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"19"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"32"}],"units":"Participants"}],"description":"(complete remission \\[CR\\]+complete response with incomplete bone marrow recovery \\[CRI\\]+partial remission \\[PR\\]+ hematologic improvement \\[HI\\]). Complete Rmission (CR) is bone marrow blasts of \\</= 5%, platelets \\>/= 100 and Absolute Neutrophil Count of \\>/= 1000. complete response with incomplete bone marrow recovery \\[CRI\\] is is bone marrow blasts of \\</= 5%, platelets \\>/= 100 or Absolute Neutrophil Count of \\>/= 1000. Hematologic improvement \\[HI\\]) is Bone Marrow Blasts \\</= 5%. Partial remission \\[PR\\] is bone marrow blasts of \\</= 5% with \\> 50% reduction, platelets \\>/= 100 and Absolute Neutrophil Count of \\>/= 1000.","groups":[{"description":"Patients receive quizartinib PO QD on days 5-28 of cycle 1 and on days 1-28 of subsequent cycles and azacitidine SC or IV over 10-40 minutes on days 1-7. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nAzacitidine: Given SC or IV\n\nQuizartinib: Given PO","id":"OG000","title":"Phase 1 Arm I (Quizartinib, Azacitidine)"},{"description":"Patients receive quizartinib PO QD on days 5-28 of cycle 1 and on days 1-28 of subsequent cycles and cytarabine SC BID on days 1-10. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nCytarabine: Given SC\n\nQuizartinib: Given PO","id":"OG001","title":"Phase 1 Arm II (Quizartinib, Cytarabine)"},{"description":"Patients receive quizartinib PO QD on days 5-28 of cycle 1 and on days 1-28 of subsequent cycles and azacitidine SC or IV over 10-40 minutes on days 1-7. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nAzacitidine: Given SC or IV\n\nQuizartinib: Given PO","id":"OG002","title":"Phase 2 Arm I (Quizartinib, Azacitidine)"},{"description":"Patients receive quizartinib PO QD on days 5-28 of cycle 1 and on days 1-28 of subsequent cycles and cytarabine SC BID on days 1-10. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nCytarabine: Given SC","id":"OG003","title":"Phase 2 Arm II (Quizartinib, Cytarabine)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"At 56 days","title":"Participants With a Response","type":"PRIMARY","unitOfMeasure":"Participants"}